Amicus Therapeutics Inc (NASDAQ:FOLD) shares traded 0.97% higher at $12.45 on Wall Street last session.
FOLD stock price is now 14.14% away from the 50-day moving average and 4.50% away from the 200-day moving average. The market capitalization of the company currently stands at $3.65B.
With the price target of $14, Morgan Stanley recently initiated with Equal-Weight rating for Amicus Therapeutics Inc (NASDAQ: FOLD).
In other news, Campbell Bradley L, President and CEO sold 11,702 shares of the company’s stock on Dec 01. The stock was sold for $129,693 at an average price of $11.08. Upon completion of the transaction, the President and CEO now directly owns 792,161 shares in the company, valued at $9.86 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 01, Executive Chairman Crowley John F sold 6,043 shares of the business’s stock. A total of $66,956 was realized by selling the stock at an average price of $11.08. This leaves the insider owning 883,791 shares of the company worth $11.0 million. Insiders disposed of 1,142,506 shares of company stock worth roughly $14.22 million over the past 1 year. A total of 3.02% of the company’s stock is owned by insiders.
During the past 12 months, Amicus Therapeutics Inc has had a low of $9.70 and a high of $14.10. As of last week, the company has a debt-to-equity ratio of 3.41, a current ratio of 2.73, and a quick ratio of 2.40. The fifty day moving average price for FOLD is $10.91 and a two-hundred day moving average price translates $11.91 for the stock.
The latest earnings results from Amicus Therapeutics Inc (NASDAQ: FOLD) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at -$0.07, beating analysts’ expectations of -$0.08 by 0.01. This compares to -$0.12 EPS in the same period last year. The net profit margin was -46.62% and return on equity was -130.63% for FOLD. The company reported revenue of $103.5 million for the quarter, compared to $81.69 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 26.7 percent. For the current quarter, analysts expect FOLD to generate $113.85M in revenue.
Amicus Therapeutics Inc(FOLD) Company Profile
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. The company also develops AT-GAA, a novel treatment paradigm for Pompe disease; and enzyme replacement therapies for Pompe diseases. It has collaboration and license agreements with Nationwide Children’s Hospital; University of Pennsylvania; and GlaxoSmithKline. The company was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
